COMPANY PROFILE

Jindu Biotech

Explore full profile

AI-driven bioscience delivering end-to-end research solutions

ChinaFounded 2022Health

Valuation $0–100M Latest valuation · 2026

Total funding $10–50M Disclosed equity funding

Unlock exact values

About Jindu Biotech

Shenzhen Jindu Biomedical Technology Co., Ltd., operating as OxTium Technology, is a company specializing in AI-driven bioscience. The company was founded by Yongcheng Jin, who holds a Ph.D. in Biomedical Engineering from the University of Oxford.

Read full description

OxTium provides end-to-end solutions through two main offerings: the BioFord™ Intelligent Research Ecosystem and the GeneLLM® Cross-modal Analysis System. BioFord™ is a cloud-native platform for life science research, while GeneLLM® is a pre-trained, multi-omics large language model framework designed to interpret biological data. These platforms are applied across several sectors, including precision diagnostics, industrial biomanufacturing, genomic breeding, and environmental bioengineering. The firm's business model includes providing bioinformatics computing services and AI algorithm development.

The company has formed strategic partnerships with organizations such as BGI Group and PUMCH Cancer Center. In June 2024, OxTium established a Joint Medical AI Innovation Center with MGI Tech, a subsidiary of BGI Group, at the China National GeneBank. The company and its team have been recognized with several awards, including an Outstanding Project Award at the 13th China Innovation and Entrepreneurship Competition in December 2024 and an Excellence Award at the Maker Beijing Innovation and Entrepreneurship Competition in October 2023.

Source: Dealroom company data

At a glance

Status: Operational
Founded: 2022
Headquarters: China
Open positions: None listed
Dealroom signal: 19.7/100
Industry: Health
Sector: Health, Genetics and genomics, Core AI, Generative AI, AI Drug Discovery
Technology: Artificial Intelligence
Business model: Manufacturing
Client focus: b2b
Links: Website

Latest news

Press, funding announcements and product moves mentioning Jindu Biotech.

See all news

Funding history

3 recorded events

Company financing events and reported valuations.

Deal type	Date	Amount	Valuation	Investors	Source
SERIES A✓Equity / VC	Jun 2026	$14M	$55M	ShenZhen GTJA Investment Group	↗
SEED✓Equity / VC	Oct 2025	$2.8M	$11M	Jiangxi Financial Holdings · Shenzhen CDF Capital · Nanshan Strategic Emerging	↗

Showing the latest 2 of 3 recorded eventsBook a demo for the full funding history →

Growth signals

Jindu Biotech website traffic

Latest recorded traffic for Jindu Biotech is 190 monthly website visits.

Latest monthly visits190

Monthly website visitsDec 2025–Jan 2026

Explore monthly traffic historyTrack growth over time and compare with peersBook a demo

Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Company	Headquarters	Status	Employees	Total funding	Valuation
DTDataInformation TechnologyAI-powered drug discovery and clinical validation platform.	China	Operational	—	$2.8M	$28M
PBProxima BioFormerly VantAI. Proximity therapeutics hijacking cellular machinery for protein degradation	New York City, United States	Operational
SBSynthesize BioAI-generated genomic data for accelerated biomedical discovery	Seattle, United States	Operational
BIBioInferaAI-powered, GPU-accelerated bioinformatics for genomics analysis	—	Operational
TAtacclab.orgGenerative AI and software solutions advancing cancer research, genomics, and pharmaceutical developments	—	Operational
EPEpsilicoGenerative AI for protein therapy design	Berlin, Germany	Operational
ALAllotropeAI architecture for preclinical crystal structure prediction.	Southampton, United Kingdom	Operational
BOBoltzAI foundation models for computational drug discovery	London, United Kingdom	Operational